Catalyst Brief

← Calendar

Readoutin 14d

Innovent Biologics (Suzhou) Co. Ltd. — IBI362

Phase 3 primary completion: IBI362 vs semaglutide in overweight or obese adults with MAFLD.

Date
Dec 2026
Type
Readout
Indication
Overweight / MAFLD

Source ↗Add to calendar

Get told when this date moves

The weekly brief is free. Pro adds reminders 7 days and 1 day before.

More from Innovent Biologics (Suzhou) Co. Ltd.

  1. Dec2026